Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. regulatory filings document the public-company record for a Nasdaq-listed precision medicine company serving transplant patients and caregivers. The company’s 8-K and proxy materials cover operating and financial results for testing services, patient and digital solutions, laboratory products, and clinical or regulatory disclosures tied to non-invasive molecular testing for organ transplantation.
CareDx filings also address material agreements, capital-structure matters for its common stock, shareholder voting items, board governance, executive compensation, inducement and other equity awards, and officer-role changes. Other-event disclosures include governance and legal-contingency materials, including shareholder derivative litigation settlement documents when filed.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg reported an automatic equity grant and updated holdings. He received a grant of 1,746 shares of Common Stock at $0.00 per share as quarterly non-employee director compensation in lieu of cash under the company’s Outside Director Compensation Policy.
Following this grant, Goldberg holds 106,438 Common Stock shares directly. A separate entry shows 91,045 Common Stock shares held indirectly by the Cavallo Trust, for which Goldberg and his spouse serve as trustees. The filing reflects routine compensation and ownership reporting rather than open-market buying or selling.
CareDx, Inc. completed two major portfolio moves. It sold its Swedish CareDx AB subsidiary and kitted lab products and software business to Eurobio Scientific for an aggregate $171.7 million in cash, sharpening focus on U.S. precision medicine testing and digital solutions.
The company also closed its acquisition of Naveris, Inc. for $161.8 million in cash plus up to $100.0 million in revenue-based milestone payments. Naveris’ NavDx test is Medicare-covered at $1,800 and generated about $35 million of revenue in 2025, helping expand CareDx’s estimated addressable market to over $12 billion across transplant, specialty oncology, and cell therapy.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a routine tax-withholding share disposition. On the vesting of restricted stock units, 8,511 shares of common stock were withheld by the company at an implied value of $29.25 per share to cover tax obligations. After this withholding, he directly holds 653,448 shares of CareDx common stock.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported a routine tax-related share disposition. On this Form 4, 997 shares of common stock were withheld by the company to cover tax obligations tied to the vesting of restricted stock units, at a value of $29.25 per share. After this withholding, Novack directly holds 111,635 shares of CareDx common stock.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a Form 4 showing a tax-related share disposition rather than an open-market trade. On this date, 2,411 shares of common stock were withheld by the company at $29.25 per share to cover tax obligations tied to vesting restricted stock units. After this withholding, she directly owned 168,287 shares, which include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026.
CareDx, Inc. executive Keith Kennedy, the CFO and COO, reported a routine tax-related share disposition linked to equity compensation. The company withheld 2,930 shares of common stock at $29.25 per share to cover tax obligations arising from the vesting of restricted stock units, rather than an open-market sale. After this withholding, Kennedy directly holds 219,924 shares of CareDx common stock. His holdings also include 1,306 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2026, reflecting ongoing participation in employee ownership programs.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported a combination of option exercises and share sales in June. He exercised employee stock options to acquire 70,000 shares of common stock at an exercise price of $8.20 per share across several transactions.
On June 26 and June 29, 2026, he sold a total of 40,000 shares of common stock in open-market transactions at a weighted average price of $29.244 per share, with individual prices ranging from $29.00 to $29.58. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance.
Following these transactions, Hanna directly holds 661,959 shares of CareDx common stock. The underlying options relate to an award vesting over four years, with one-quarter vesting on April 15, 2025 and the remainder vesting monthly thereafter, and expiring on April 14, 2034.
Common stockholder filed a Form 144 to sell 39,500 shares of common stock, dated 06/29/2026. The filing states the sale arises from an exercise of stock options and lists cash as the method.
The notice also lists recent 10b5-1 sales by John Hanna during the prior three months: 21,998, 17,683, 10,282, 4,835 and 100 shares with the corresponding proceeds shown.
CareDx, Inc. President and CEO John Walter Hanna Jr. reported an open-market sale of 17,683 shares of Common Stock on June 15, 2026 at a weighted average price of $24.0274 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 13, 2024.
After this transaction, he continues to directly hold 631,959 shares of CareDx common stock, according to the filing.
CareDx, Inc. director Hannah Valantine reported both an equity grant and a share sale. On June 12, 2026, she acquired 9,795 shares of Common Stock as a grant with no cash paid, represented by restricted stock units that vest 100% on the earlier of the one-year anniversary of grant or immediately before the first Annual Meeting after the grant date, subject to continuous service. On June 15, 2026, she sold 12,103 shares of Common Stock in an open-market transaction at a weighted average price of $23.1123 per share, with individual sale prices ranging from $23.00 to $23.30. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025, and she held 36,686 shares directly after the sale.